Treatment Options for Primary XXXX : A Short Comprehensive Review.

@entity1 @entity417 @entity500 @entity786 @entity5506 @entity479
Until now, treatment of primary @entity5506 of the warm type (wAIHA) is primarily based on immunosuppression. However, many @entity1 do not respond adequately to treatment, and treated @entity1 may develop severe side effects due to uncontrolled, mixed and/or long-lasting immunosuppression. Unfortunately, the newly used therapeutic monoclonal antibodies are unspecific and remain frequently ineffective. Thus, development of a specific therapy for AIHA is necessary. The ideal therapy would be the identification and elimination of the causative origin of autoimmunization and/or the correction or reprogramming of the dysregulated immune components. Blood transfusion is the most rapidly effective measure for @entity1 who develop or may develop @entity417 . Although some effort has been made to guide physicians on how to adequately treat @entity1 with AIHA, a number of individual aspects should be considered prior to treatment. Based on my serological and clinical experience and the analysis of evidence-based studies, we remain far from any optimized therapeutic measures for all AIHA @entity1 . Today, the old standard therapy using controlled @entity479 administration, with or without @entity500 or @entity786 , is, when complemented with erythropoiesis-stimulating agents, still the most effective therapy in wAIHA. Rituximab or other monoclonal antibodies may be used instead of splenectomy in therapy-refractory @entity1 .
